PR
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

PR Trademark

Serial Number: 79397083 • Registration: 7717932

PR is a trademark filed by PharmaGend Global Medical Services Pte Ltd on March 18, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

PharmaGend Global Medical Services Pte Ltd (2 trademarks)

3 TUAS SOUTH AVENUE 4

Entity Type: 24

Trademark Details

Filing Date

March 18, 2024

Registration Date

March 11, 2025

Published for Opposition

January 21, 2025

Goods & Services

Custom assembling of materials for others, namely, multi-layer coated tablets, liquid filled hard gelatin capsules, bottle filling activities; providing information relating to material treatment; processing of metal surfaces using precision grinding techniques; irradiation of food; cryopreservation services; food and drink processing for others; processing of chemicals; sorting of waste and recyclable material; bookbinding; grinding

Bases being chemical preparations of pharmaceutical drug product formulation, manufacturing, packing, testing and release to market; salts being chemical preparations for improved therapeutic actions, additional indication, drug product stability enhancement and bioavailability improvement in pharmaceutical products; cellulose derivatives being chemical preparations for use as excipients in drug formulation, providing controlled release and delayed release of drug enhancing bioavailability of drug product; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; animal extracts in the nature of from bovine source for use in pharmaceutical and nutraceutical manufacturing, particularly in dietary supplements and therapeutic drug products as well as nutritional products for the food industry; biological preparations for use in industry and science, other than for medical or veterinary purposes; diagnostic preparations, other than for medical or veterinary purposes; plant extracts, other than essential oils, for use in the manufacture of pharmaceuticals; plant extracts, other than essential oils, for use in the manufacture of cosmetics

Import-export agency services; business management consultancy; outsourcing services; business research; wholesale store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; retail store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies

Immunological products for intravenous injections, namely for immune system support, such as vaccines, monoclonal antibodies (mAbs), Cytokines/Cytokine Inhibitors; tablets for medicines, specifically diuretic, anti-fungal, digestive disorders, anti-inflammatory, antidiabetic, dementia tablets for treating common infections and chronic diseases; drinking water fused with electrolytes, salts, hemodialysis solution, suitable for rehydration and maintenance therapy for medical purposes; gelatin capsules sold empty for pharmaceuticals; slimming pills; medicinal ointments for treating skin conditions, such as dermatitis, wounds, or burns, offering antiseptic and healing properties; medicines for human purposes for treating various ailments ranging from cough and cold medicines to cardiac disease; Nutraceutical preparations for therapeutic or medical purposes for treating digestive disorders, vitamin deficiency, therapeutic dosage of Vitamins; biochemical medicines for treating metabolic disorders, hormonal imbalances, autoimmune diseases, and rare genetic conditions, such as enzyme replacement therapies, peptide-based drugs, and nucleotide-based therapies; pharmaceutical preparations for treating heart diseases, asthma, obesity, diabetes, hypertension

Technological research in the field of formulation development, scale-up batches, formulation refinement, drug delivery systems, and optimization of production processes; conducting technical project studies, namely, bioequivalence studies, clinical trial study design and regulatory compliance research in the pharmaceutical field; scientific laboratory services; providing scientific information, advice and consultancy relating to carbon offsetting; quality control for others; industrial inspection serialization of products, medical devices; quality assessment of pharmaceutical manufacturing processes, process validation, focusing on batch consistency, contamination control, impurity profiling and GMP compliance; biological research; Medical and scientific research, namely, conducting clinical trials for others; medical research

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 22, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 5, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Nov 5, 2025 OPNR
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 18, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 25, 2025 FICS
FINAL DISPOSITION PROCESSED
Sep 24, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 12, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 11, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 11, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 21, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jan 21, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 15, 2025 NONP
WITHDRAWN FROM ISSUE - OG REVIEW QUERY
Jan 10, 2025 ISCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 27, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 21, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 21, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 21, 2024 TROA
REFUSAL PROCESSED BY IB
Oct 19, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 2, 2024 RFCS
REFUSAL PROCESSED BY MPU
Oct 2, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 27, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 26, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 25, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 10, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 10, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 6, 2024 REPR